In vivo selection of human embryonic stem cell-derived cells expressing methotrexate-resistant dihydrofolate reductase

Gene Therapy

Volumn 17, Issue 2, 2010, Pages 238-249

  Gori, J L ^a   Tian, X ^b   Swanson, D ^a   Gunther, R ^a   Shultz, L D ^c   McIvor, R S ^a   Kaufman, D S ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c JACKSON LABORATORY   (United States)

Author keywords

Dihydrofolate reductase; Embryonic stem cells; Methotrexate

Indexed keywords

CD34 ANTIGEN; CD45 ANTIGEN; DIHYDROFOLATE REDUCTASE; METHOTREXATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW; CELL BASED GENE THERAPY; CELL DIFFERENTIATION; CELL SELECTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG OVERDOSE; DRUG TOLERABILITY; EMBRYONIC STEM CELL; ENDOTHELIUM CELL; ENGRAFTMENT; FEMALE; IMMUNE DEFICIENCY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TERATOMA;

ANIMALS; BONE MARROW; CELL DIFFERENTIATION; CELL LINE; DRUG RESISTANCE; EMBRYONIC STEM CELLS; GENE THERAPY; GRAFT SURVIVAL; HUMANS; METHOTREXATE; MICE; MICE, INBRED NOD; MICE, SCID; STEM CELL TRANSPLANTATION; TERATOMA; TETRAHYDROFOLATE DEHYDROGENASE;

MUS;

EID: 76749141897     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.131     Document Type: Article

References (54)

1. Halene S, Kohn DB. Gene therapy using hematopoietic stem cells: Sisyphus approaches the crest. Hum Gene Ther 2000; 11: 1259-1267.
2. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193. (Pubitemid 34984579)
3. Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2003; 348: 255-256.
4. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
5. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
6. Gerull S, Beard BC, Peterson LJ, Neff T, Kiem HP. In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. Hum Gene Ther 2007; 18: 451-456.
7. Neff T, Horn PA, Peterson LJ, Thomasson BM, Thompson J, Williams DA et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J Clin Invest 2003; 112: 1581-1588.
8. Cornetta K, Croop J, Dropcho E, Abonour R, Kieran MW, Kreissman S et al. A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of CD34+ peripheral blood cells with O6-methylguanine DNA methyl-transferase. Cancer Gene Ther 2006; 13: 886-895.
9. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068.
10. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314.
11. Bertino JR. Karnofsky memorial lecture. Ode to methotrexate. J Clin Oncol 1993; 11: 5-14.
12. Gori JL, Podetz-Pedersen K, Swanson D, Karlen AD, Gunther R, Somia NV et al. Protection of mice from methotrexate toxicity by ex vivo transduction using lentivirus vectors expressing drug-resistant dihydrofolate reductase. J Pharmacol Exp Ther 2007; 322: 989-997.
13. Allay JA, Galipeau J, Blakley RL, Sorrentino BP. Retroviral vectors containing a variant dihydrofolate reductase gene for drug protection and in vivo selection of hematopoietic cells. Stem Cells 1998; 16(Suppl 1): 223-233.
14. Persons DA, Allay JA, Bonifacino A, Lu T, Agricola B, Metzger ME et al. Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors. Blood 2004; 103: 796-803.
15. Kaufman DS, Hanson ET, Lewis RL, Auerbach R, Thomson JA. Hematopoietic colony-forming cells derived from human embryonic stem cells. Proc Natl Acad Sci USA 2001; 98: 10716-10721. (Pubitemid 32878687)
16. Tian X, Morris JK, Linehan JL, Kaufman DS. Cytokine requirements differ for stroma and embryoid body-mediated hemato-poiesis from human embryonic stem cells. Exp Hematol 2004; 32: 1000-1009.
17. Tian X, Kaufman DS. Hematopoietic development of human embryonic stem cells in culture. Methods Mol Biol 2008; 430: 119-133.
18. Vodyanik MA, Bork JA, Thomson JA, Slukvin II. Human embryonic stem cell-derived CD34+ cells: efficient production in the coculture with OP9 stromal cells and analysis of lymphohematopoietic potential. Blood 2005; 105: 617-626.
19. Qiu C, Olivier EN, Velho M, Bouhassira EE. Globin switches in yolk sac-like primitive and fetal-like definitive red blood cells produced from human embryonic stem cells. Blood 2008; 111: 2400-2408.
20. Chadwick K, Wang L, Li L, Menendez P, Murdoch B, Rouleau A et al. Cytokines and BMP-4 promote hematopoietic differentiation of human embryonic stem cells. Blood 2003; 102: 906-915.
21. Woll PS, Martin CH, Miller JS, Kaufman DS. Human embryonic stem cell-derived NK cells acquire functional receptors and cytolytic activity. J Immunol 2005; 175: 5095-5103.
22. Woll PS, Grzywacz B, Tian X, Marcus RK, Knorr DA, Verneris MR et al. Human embryonic stem cells differentiatiate into a homogeneous population of natural killer cells with highly potent in vivo antitumor activity. Blood 2009; 113: 6094-6101.
23. Ma F, Ebihara Y, Umeda K, Sakai H, Hanada S, Zhang H et al. Generation of functional erythrocytes from human embryonic stem cell-derived definitive hematopoiesis. Proc Natl Acad Sci USA 2008; 105: 13087-13092.
24. Qiu C, Hanson E, Olivier E, Inada M, Kaufman DS, Gupta S et al. Differentiation of human embryonic stem cells into hematopoie-tic cells by coculture with human fetal liver cells recapitulates the globin switch that occurs early in development. Exp Hematol 2005; 33: 1450-1458.
25. Lu SJ, Feng Q, Park JS, Vida L, Lee BS, Strausbauch M et al. Biologic properties and enucleation of red blood cells from human embryonic stem cells. Blood 2008; 112: 4475-4484.
26. Ledran MH, Krassowska A, Armstrong L, Dimmick I, Renstrom J, Lang R et al. Efficient hematopoietic differentiation of human embryonic stem cells on stromal cells derived from hemato-poietic niches. Cell Stem Cell 2008; 3: 85-98.
27. Tian X, Woll PS, Morris JK, Linehan JL, Kaufman DS. Hematopoietic engraftment of human embryonic stem cell-derived cells is regulated by recipient innate immunity. Stem Cells 2007; 24: 1370-1380.
28. Wang L, Menendez P, Shojaei F, Li L, Mazurier F, Dick JE et al. Generation of hematopoietic repopulating cells from human embryonic stem cells independent of ectopic HOXB4 expression. J Exp Med 2005; 201: 1603-1614.
29. Narayan AD, Chase JL, Lewis RL, Tian X, Kaufman DS, Thomson JA et al. Human embryonic stem cell-derived hematopoietic cells are capable of engrafting primary as well as secondary fetal sheep recipients. Blood 2006; 107: 2180-2183.
30. Pfeifer A, Ikawa M, Dayn Y, Verma IM. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci USA 2002; 99: 2140-2145.
31. Wilber A, Linehan JL, Tian X, Woll PS, Morris JK, Belur LR et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem Cells 2007; 25: 2919-2927.
32. Giudice A, Trounson A. Genetic modification of human embryonic stem cells for derivation of target cells. Cell Stem Cell 2008; 2: 422-433.
33. Ben-Dor I, Itsykson P, Goldenberg D, Galun E, Reubinoff BE. Lentiviral vectors harboring a dual-gene system allow high and homogeneous transgene expression in selected polyclonal human embryonic stem cells. Mol Ther 2006; 14: 255-267.
34. Xu XQ, Zweigerdt R, Soo SY, Ngoh ZX, Tham SC, Wang STet al. Highly enriched cardiomyocytes from human embryonic stem cells. Cytotherapy 2008; 10: 376-389.
35. Gallo P, Grimaldi S, Latronico MV, Bonci D, Pagliuca A, Gallo P et al. A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells. Gene Therapy 2008; 15: 161-170.
36. Davis RP, Ng ES, Costa M, Mossman AK, Sourris K, Elefanty AG et al. Targeting a GFP reporter gene to the MIXL1 locus of human embryonic stem cells identifies human primitive streak-like cells and enables isolation of primitive hematopoietic precursors. Blood 2008; 111: 1876-1884.
37. Huber I, Itzhaki I, Caspi O, Arbel G, Tzukerman M, Gepstein A et al. Identification and selection of cardiomyocytes during human embryonic stem cell differentiation. FASEB J 2007; 21: 2551-2563.
38. Lavon N, Yanuka O, Benvenisty N. The effect of overexpression of Pdx1 and Foxa2 on the differentiation of human embryonic stem cells into pancreatic cells. Stem Cells 2006; 24: 1923-1930.
39. Zwaka TP, Thomson JA. Homologous recombination in human embryonic stem cells. Nat Biotechnol 2003; 21: 319-321.
40. Agarwal S, Nikolai B, Yamaguchi T, Lech P, Somia NV. Construction and use of retroviral vectors encoding the toxic gene barnase. Mol Ther 2006; 14: 555-563.
41. Hill KL, Kaufman DS. Hematopoietic differentiation of human embryonic stem cells by cocultivation with stromal layers. Curr Prot Stem Cell Biol 2008; Chapter 1: Unit 1F 6.
42. Woll PS, Morris JK, Painschab MS, Marcus RK, Kohn AD, Biechele TL et al. Wnt signaling promotes hematoendothelial cell development from human embryonic stem cells. Blood 2008; 111: 122-131.
43. Zambidis ET, Park TS, Yu W, Tam A, Levine M, Yuan X et al. Expression of ACE (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008; 112: 3601-3614.
44. Warlick CA, Sweeney CL, McIvor RS. Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition. Biochem Pharmacol 2000; 59: 141-151.
45. Allay JA, Persons DA, Galipeau J, Riberdy JM, Ashmun RA, Blakley RL et al. In vivo selection of retrovirally transduced hematopoietic stem cells. Nat Med 1998; 4: 1136-1143.
46. Allay JA, Spencer HT, Wilkinson SL, Belt JA, Blakley RL, Sorrentino BP. Sensitization of hematopoietic stem and progenitor cells to trimetrexate using nucleoside transport inhibitors. Blood 1997; 90: 3546-3554.
47. Neff T, Beard BC, Peterson LJ, Anandakumar P, Thompson J, Kiem HP. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 2005; 105: 997-1002.
48. Kreklau EL, Pollok KE, Bailey BJ, Liu N, Hartwell JR, Williams DA. Hematopoietic expression of O6-methylguanine DNA methly-transferase-P140K allows intenstive treatment of human glioma xenografts with combination O6-benzylguanine and 1,3-bis-(2-chloroethyl)-1-nitrosourea. Mol Cancer Ther 2003; 2: 1321-1329.
49. Budak-Alpdogan T, Alpdogan O, Banerjee D, Wang E, Moore MA, Bertino JR. Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene. Mol Ther 2004; 10: 574-584.
50. Pollok KE, Hartwell JR, Braber A, Cooper RJ, Jansen M, Ragg S et al. In vivo selection of human hematopoietic cells in a xenograft model using combined pharmacologic and genetic manipulations. Hum Gene Ther 2003; 14: 1703-1714.
51. Cai S, Hartwell JR, Cooper RJ, Juliar BE, Kreklau E, Abonour R et al. In vivo effects of myeloablative alkylator therapy on survival and differentiation of MGMTP140K-transduced human G-CSF-mobilized peripheral blood cells. Mol Ther 2006; 13: 1016-1026.
52. Ng ES, Davis RP, Azzola L, Stanley EG, Elefanty AG. Forced aggregation of defined numbers of human embryonic stem cells into embryoid bodies fosters robust, reproducible hematopoietic differentiation. Blood 2005; 106: 1601-1603.
53. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Prot 2006; 1: 241-245.
54. Carr F, Medina WD, Dube S, Bertino JR. Genetic transformation of murine bone marrow cells to methotrexate resistance. Blood 1983; 62: 180-185.